Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cervical fusion & disc arthroplasty cases in Maine: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (208 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 4 | 180 | 39% |
| 2020 | 1 | 144 | 46% |
| 2021 | 1 | 133 | 51% |
| 2022 | 1 | 115 | 56% |
| 2023 | 0 | 112 | 59% |
| 2024 | 0 | 107 | 62% |
| 2025 from claims | – | 151 123–178 | 63% |
| 2026 forecast | – | 154 122–195 | 63% |
| 2027 forecast | – | 155 117–207 | 64% |
| 2028 forecast | – | 156 112–217 | 64% |
| 2029 forecast | – | 156 108–227 | 65% |
| 2030 forecast | – | 157 105–236 | 65% |
ACDF, posterior cervical fusion, cervical total disc replacement. Professional codes (what the surgeon bills): CPT 22551, 22600, 22856; the hospital bills MS-DRG 471, 472, 473, 429, 430.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 56% inpatient hospital, 44% hospital outpatient.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 35 | 1,837−1%/yr | −1%/yr | 1.0 | 2% | 1,980 in 2030+1.2%/yr |
| Pennsylvania | 23 | 1,756−3.9%/yr | −3.9%/yr | 1.2 | 0% | 1,870 in 2030+1%/yr |
| Massachusetts | 23 | 1,123−2.2%/yr | −2.2%/yr | 1.2 | 0% | 1,310 in 2030+2.6%/yr |
| New Jersey | 15 | 911+1.2%/yr | +1.2%/yr | 0.8 | 0% | 1,020 in 2030+1.9%/yr |
| Connecticut | 4 | 370−6.9%/yr | −6.9%/yr | 1.1 | 0% | 370 in 2030+0.2%/yr |
| New Hampshire | 2 | 169−7.9%/yr | −7.9%/yr | 0.7 | 0% | 180 in 2030+0.7%/yr |
| Rhode Island | 0 | 107+1.6%/yr | +1.6%/yr | 1.1 | 0% | 220 in 2030+13%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 7 | 249−15%/yr | −15%/yr | 1.50.6× | 0% | 280 in 2030+2%/yr |
Cervical fusion & disc arthroplasty in every state, and its device makers · Every procedure market in Maine · Every state · Compare with New York
Medtronic leads with 51% of company spending on these surgeons in 2025, −32 pts on 2024.
In 2025, 4 companies reported engagement with Maine’s surgeons worth $453 in consulting, speaking, meals and travel tied to these products. Royalties are left out.
FDA, last 12 months: 69 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
No metro breakdown yet.